Unpacking the Evidence for Their Use Today and Tomorrow

Digging Deep on Shared Decision-Making

Looking Beyond Hemoglobin A1c

Translating Guidelines Into Patient Care

A Case-Based Look at Exacerbation Prevention

A Guide to Healthcare Advances for Specialist Clinicians

Debates and Discussions About Managing Moderate-to-Severe Disease

Catch up with experts on the latest evidence related to HIV prevention, rapid-start antiretroviral (ART) therapy, and HCV screening and treatment for people who inject drugs—the population at highest risk of transmission. These 15-minute expert interviews will provide the epidemiologic trends that underlie the imperative for HIV preexposure prophylaxis (PrEP), present HIV treatment as prevention (TasP), and emphasize the feasibility, efficacy, and ease of treating HCV-infected PWID.

Three-part CME Series - Earn 2.0 Total Credits

This series of 3 unique, case-based, interactive online activities was developed to improve the care of patients with HIV. The instructional design incorporates the latest evidence-based guidelines for HIV management into clinical scenarios of different patient populations. Case topics cover treatment initiation, rapid antiretroviral therapy (ART) protocols, considerations for people with substance use, switching regimens for simplification or comorbidities, and treatment and adherence in transgender patients. Sample patient types include:

          - A newly diagnosed transgender female 

          - A newly diagnosed young male who has sex with men (MSM) with a   

            history of recreational drug use

          - A well-informed, HIV treatment-experienced patient looking for

            updates on switching regimens and emerging approaches to treatment

Implications for PCSK9 Inhibitors in Clinical Practice

Interdisciplinary Management of Patients With Severe Asthma

Optimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis

Physicians need further education to fully understand and implement current advanced therapies and distinguish the pathways of disease and targets addressed by newer therapies. This educational activity will provide key clinical data on new and emerging treatments, focusing on the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the context of evolving understanding of disease immunopathogenesis.

Mechanistic Insights and Evolving Treatment Options

This educational activity will address the pharmacist’s critical role in HCV elimination, guideline-based HCV testing and identification of persons at risk, harm-reduction–informed patient education, and selected models for effective linkage to HCV treatment.

Debates & Discussions on the Evolving Role of JAK Inhibitors

Collaborative Care for Better Patient Outcomes

HIV as a Chronic Disease: A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

Debates and Discussions Around Cardiovascular and Renal Outcomes

Why It Matters in OB/GYN Practice Today